Literature DB >> 25244983

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

F Cardoso1, A Costa2, L Norton3, E Senkus4, M Aapro5, F André6, C H Barrios7, J Bergh8, L Biganzoli9, K L Blackwell10, M J Cardoso11, T Cufer12, N El Saghir13, L Fallowfield14, D Fenech15, P Francis16, K Gelmon17, S H Giordano18, J Gligorov19, A Goldhirsch20, N Harbeck21, N Houssami22, C Hudis23, B Kaufman24, I Krop25, S Kyriakides26, U N Lin25, M Mayer27, S D Merjaver28, E B Nordström29, O Pagani30, A Partridge31, F Penault-Llorca32, M J Piccart33, H Rugo34, G Sledge35, C Thomssen36, L Van't Veer37, D Vorobiof38, C Vrieling39, N West40, B Xu41, E Winer25.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25244983     DOI： 10.1016/j.breast.2014.08.009

Source DB:  PubMed          Journal:  Breast        ISSN： 0960-9776            Impact factor:   4.380


× No keyword cloud information.
  96 in total

1.  AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.

Authors:  Cornelia Liedtke; Marc Thill; Volker Hanf; Florian Schuütz
Journal:  Breast Care (Basel)       Date:  2015-06-18       Impact factor: 2.860

2.  P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice.

Authors:  André Filipe Vieira; Maria Rita Dionísio; Madalena Gomes; Jorge F Cameselle-Teijeiro; Manuela Lacerda; Isabel Amendoeira; Fernando Schmitt; Joana Paredes
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

3.  ABC4 Consensus: Assessment by a German Group of Experts.

Authors:  Nadia Harbeck; Diana Lüftner; Norbert Marschner; Michael Untch; Doris Augustin; Susanne Briest; Johannes Ettl; Renate Haidinger; Lothar Müller; Volkmar Müller; Eugen Ruckhäberle; Rachel Wuerstlein; Christoph Thomssen
Journal:  Breast Care (Basel)       Date:  2018-02-15       Impact factor: 2.860

4.  Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.

Authors:  Ganesan Vaidyanathan; Darryl McDougald; Jaeyeon Choi; Eftychia Koumarianou; Douglas Weitzel; Takuya Osada; H Kim Lyerly; Michael R Zalutsky
Journal:  J Nucl Med       Date:  2016-02-18       Impact factor: 10.057

5.  ABC3 Consensus: Assessment by a German Group of Experts.

Authors:  Christoph Thomssen; Doris Augustin; Johannes Ettl; Renate Haidinger; Hans-Joachim Lück; Diana Lüftner; Frederik Marmé; Norbert Marschner; Lothar Müller; Friedrich Overkamp; Eugen Ruckhäberle; Marc Thill; Michael Untch; Rachel Wuerstlein; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2016-01-29       Impact factor: 2.860

6.  Association of human epidermal growth factor receptor 2 status with ipsilateral breast tumor recurrence and resistance to endocrine therapy.

Authors:  Makoto Ishitobi; Mizuho Shiba; Takahiro Nakayama; Hiroki Koyama; Yasuhiro Tamaki
Journal:  Mol Clin Oncol       Date:  2015-03-30

Review 7.  Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines.

Authors:  A A Joy; M Ghosh; R Fernandes; M J Clemons
Journal:  Curr Oncol       Date:  2015-03       Impact factor: 3.677

8.  4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.

Authors:  F Cardoso; E Senkus; A Costa; E Papadopoulos; M Aapro; F André; N Harbeck; B Aguilar Lopez; C H Barrios; J Bergh; L Biganzoli; C B Boers-Doets; M J Cardoso; L A Carey; J Cortés; G Curigliano; V Diéras; N S El Saghir; A Eniu; L Fallowfield; P A Francis; K Gelmon; S R D Johnston; B Kaufman; S Koppikar; I E Krop; M Mayer; G Nakigudde; B V Offersen; S Ohno; O Pagani; S Paluch-Shimon; F Penault-Llorca; A Prat; H S Rugo; G W Sledge; D Spence; C Thomssen; D A Vorobiof; B Xu; L Norton; E P Winer
Journal:  Ann Oncol       Date:  2018-08-01       Impact factor: 32.976

Review 9.  Breast cancer in 2014: A call back to reality!

Authors:  Fatima Cardoso; Elżbieta Senkus
Journal:  Nat Rev Clin Oncol       Date:  2015-01-06       Impact factor: 66.675

10.  Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells.

Authors:  Armando M Marrufo; Stephen O Mathew; Pankaj Chaudhary; Joseph D Malaer; Jamboor K Vishwanatha; Porunelloor A Mathew
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.